License and Asset Purchase Agreement Sample Contracts
CONFIDENTIAL LICENSE AND ASSET PURCHASE AGREEMENT DATED AS OF JANUARY 23, 2012 BETWEEN SPECTRUM PHARMACEUTICALS CAYMAN, L.P.License and Asset Purchase Agreement • May 4th, 2017 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • New York
This License and Asset Purchase Agreement, dated as of January 23, 2012 (the “Execution Date”) (as amended or otherwise modified, the “Agreement”), is between Spectrum Pharmaceuticals Cayman, L.P., an Exempted Limited Partnership organized under the laws of the Cayman Islands (“Purchaser”) and Bayer Pharma AG, a German aktiengesellschaft (“Bayer”).
LICENSE AND ASSET PURCHASE AGREEMENT DATED AS OF NOVEMBER 16, 2015 BETWEEN SPECTRUM PHARMACEUTICALS CAYMAN, L.P.License and Asset Purchase Agreement • June 10th, 2016 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • New York
This License and Asset Purchase Agreement, dated as November 16, 2015 (the “Effective Date”) (as amended or otherwise modified, the “Agreement”), is between Spectrum Pharmaceuticals Cayman, L.P., an Exempted Limited Partnership organized under the laws of the Cayman Islands (“Spectrum”) and Mundipharma International Corporation Limited, a Bermuda corporation (“Purchaser”).
EXHIBIT 10.14 LICENSE AND ASSET PURCHASE AGREEMENT This LICENSE AND ASSET PURCHASE AGREEMENT (this "Agreement") is made and entered into as of February 27, 1998 (the "Effective Date"), by and between Global MAINTECH Corporation, a Minnesota...License and Asset Purchase Agreement • March 31st, 1998 • Global Maintech Corp • Electronic computers • Minnesota
LICENSE AND ASSET PURCHASE AGREEMENT BY AND BETWEEN VERACYTE, INC. AND NANOSTRING TECHNOLOGIES, INC. Dated as of December 3, 2019License and Asset Purchase Agreement • December 4th, 2019 • NanoString Technologies Inc • Biological products, (no disgnostic substances) • Delaware
This LICENSE AND ASSET PURCHASE AGREEMENT, dated as of December 3, 2019 (this “Agreement”), is by and between Veracyte, Inc., a Delaware corporation (“Veracyte”) and NanoString Technologies, Inc., a Delaware corporation (“NanoString”). NanoString and Veracyte are each referred to as a “Party” and collectively as the “Parties”.
Exhibit 10.20 LICENSE AND ASSET PURCHASE AGREEMENT LICENSE AND ASSET PURCHASE AGREEMENT (this "Agreement"), dated as of March 20, 2002, by and between Ecesis LLC, a Delaware limited liability company ("Ecesis"), Polychem Corporation, a Pennsylvania...License and Asset Purchase Agreement • May 24th, 2002 • Conmat Technologies Inc • Plastic material, synth resin/rubber, cellulos (no glass) • Pennsylvania
LICENSE AND ASSET PURCHASE AGREEMENTLicense and Asset Purchase Agreement • July 12th, 2022 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS LICENSE AND ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of July 11, 2022 (the “Execution Date”), by and between JACOBUS PHARMACEUTICAL COMPANY, INC., a New Jersey corporation with offices located at IRL Building, 31 Schalks Crossing Road, Plainsboro, NJ (“Jacobus”) and CATALYST PHARMACEUTICALS, INC., a Delaware corporation with offices located at 355 Alhambra Circle, Suite 801, Coral Gables, FL (“Catalyst”). Jacobus and Catalyst are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AND ASSET PURCHASE AGREEMENTLicense and Asset Purchase Agreement • December 14th, 2006 • Biovest International Inc • Pharmaceutical preparations • Delaware
AMENDMENT TO LICENSE AND ASSET PURCHASE AGREEMENTLicense and Asset Purchase Agreement • May 6th, 2016 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT (“Amendment”) is entered into as of February 29, 2016 (the “Effective Date”) by and between Spectrum Pharmaceuticals Cayman, L.P. (“Purchaser”) and Bayer Pharma AG (“Bayer”).
Via E-mailLicense and Asset Purchase Agreement • February 10th, 2020
LICENSE AND ASSET PURCHASE AGREEMENT DATED AS OF MARCH 30, 2009 BETWEEN GENZYME CORPORATION, AND BAYER SCHERING PHARMA AGLicense and Asset Purchase Agreement • August 9th, 2010 • Genzyme Corp • Biological products, (no disgnostic substances) • New York
This License Agreement (the “Agreement”), dated as of May 29, 2009 (the “Effective Date”), is between Genzyme Corporation (“Genzyme”) and Alcafleu Management GmbH & Co. KG (“Alcafleu”).
Via E-mailLicense and Asset Purchase Agreement • February 20th, 2020